tmem267 Antibody

What is TMEM267 and why is it significant for research?

TMEM267, also known as C5orf28, is a protein-coding gene that encodes a transmembrane protein. Though less extensively characterized than some other transmembrane proteins, emerging research suggests its potential significance in biological processes. This protein appears to be structurally related to TMEM268, which has been shown to play a role in anti-infectious immune responses and integrin signaling pathways . The study of TMEM267 offers opportunities to expand our understanding of membrane protein biology and potentially identify new therapeutic targets.

What types of TMEM267 antibodies are available for research?

Current research utilizes several types of TMEM267 antibodies:

Most commercially available antibodies target human TMEM267, particularly the N-terminal region (amino acids 1-76) .

What are the optimal storage conditions for TMEM267 antibodies?

For maximum stability and antibody performance, TMEM267 antibodies should be:

• Stored at -20°C for long-term preservation

• Aliquoted to avoid repeated freeze/thaw cycles that can diminish activity

• For fluorophore-conjugated antibodies (e.g., FITC conjugates), storage should include protection from light to prevent photobleaching

• Typically supplied in buffers containing 0.01M PBS (pH 7.4), 0.03% Proclin-300, and 50% Glycerol for stability

What are the recommended starting dilutions for different applications?

Based on literature and manufacturer recommendations:

• For immunofluorescence (IF/ICC): 1/50 - 1/200 dilution is recommended as a starting point

• For ELISA applications: Optimal dilutions should be determined experimentally by the researcher

• When using blocking peptides: A 100x molar excess of the protein fragment control based on the antibody concentration is recommended for blocking experiments

How can I validate the specificity of TMEM267 antibodies?

Rigorous validation is critical for ensuring reliable experimental results:

• Blocking peptide experiments: Pre-incubate the antibody with a TMEM267 control fragment (such as recombinant TMEM267 aa 32-55 fragment) for 30 minutes at room temperature before application. Signal reduction confirms specificity .

• Knockout/knockdown controls: Compare staining between wild-type samples and those where TMEM267 has been genetically depleted. The research methodology used for TMEM268 provides a model approach, where knockout mice were generated using CRISPR-Cas9 technology .

• Western blot analysis: Verify that the antibody detects a band of the expected molecular weight for TMEM267.

• Cross-reactivity testing: Test the antibody against samples from different species to confirm the specificity matches manufacturer claims.

What positive and negative controls should be included in TMEM267 antibody experiments?

Positive controls:

• Cell lines or tissues known to express TMEM267

• Recombinant TMEM267 protein (full-length or fragments)

• Overexpression systems (transfected cells expressing TMEM267)

Negative controls:

• Secondary antibody-only controls (omitting primary antibody)

• Isotype controls (non-specific rabbit IgG at the same concentration)

• Pre-immune serum (for polyclonal antibodies)

• Blocking peptide controls as described above

• TMEM267 knockout/knockdown samples where available

How do I interpret discrepancies in TMEM267 detection between different antibodies?

Inconsistencies may arise due to:

• Epitope differences: Antibodies targeting different regions of TMEM267 may yield different results depending on protein conformation, post-translational modifications, or protein-protein interactions.

• Antibody quality variations: Differences in specificity, affinity, and lot-to-lot variability can affect detection.

• Application-specific performance: An antibody that works well in ELISA may not perform optimally in immunofluorescence.

When faced with discrepancies:

• Compare antibody epitopes and determine if they target different regions

• Validate each antibody individually using the approaches outlined in question 2.1

• Consider using multiple antibodies targeting different epitopes to increase confidence in findings

• Document all validation experiments meticulously for publication

How can I optimize immunofluorescence protocols for TMEM267 detection?

For successful IF/ICC detection of TMEM267:

• Fixation optimization:

  • Test multiple fixation methods (4% paraformaldehyde, methanol, or acetone)

  • Optimize fixation time (typically 10-20 minutes at room temperature)

  • For membrane proteins like TMEM267, gentle permeabilization is critical

• Antigen retrieval considerations:

  • For formaldehyde-fixed tissues, heat-induced epitope retrieval may improve detection

  • Citrate buffer (pH 6.0) or Tris-EDTA (pH 9.0) can be tested

• Blocking and antibody incubation:

  • Use 5-10% normal serum from the same species as the secondary antibody

  • Include 0.1-0.3% Triton X-100 for membrane permeabilization

  • Optimize primary antibody concentration (starting with 1:50 - 1:200 dilution)

  • Extend primary antibody incubation time (overnight at 4°C often yields better results)

• Signal enhancement strategies:

  • Consider tyramide signal amplification for weak signals

  • Use high-sensitivity detection systems for low-abundance targets

What are the considerations for using TMEM267 antibodies in co-localization studies?

When designing co-localization experiments:

• Antibody compatibility:

  • Ensure primary antibodies are from different host species

  • If using multiple rabbit antibodies, consider direct conjugation or sequential staining protocols

• Fluorophore selection:

  • Choose fluorophores with minimal spectral overlap

  • For FITC-conjugated TMEM267 antibodies (excitation/emission: 499/515nm) , pair with far-red or red fluorophores

• Controls for co-localization:

  • Include single-stained controls for each antibody

  • Use known co-localizing and non-co-localizing proteins as controls

  • Perform antibody cross-reactivity controls

• Quantitative analysis:

  • Use appropriate co-localization coefficients (Pearson's, Manders', etc.)

  • Perform statistical analysis on multiple cells/fields

  • Consider 3D analysis for volumetric co-localization

What are common causes of high background when using TMEM267 antibodies?

High background can significantly reduce signal-to-noise ratio. Common causes and solutions include:

• Insufficient blocking:

  • Increase blocking time (1-2 hours at room temperature)

  • Try different blocking agents (BSA, normal serum, commercial blockers)

  • Add 0.1-0.3% Tween-20 to washing buffers

• Antibody concentration issues:

  • Titrate antibody to determine optimal concentration

  • For TMEM267 antibodies, start with manufacturer recommendations (1:50-1:200) and adjust

• Non-specific binding:

  • Pre-adsorb antibody with tissue powder

  • Include 1-5% normal serum from the host species in antibody diluent

  • Consider using more stringent washing conditions

• Fixation artifacts:

  • Optimize fixation protocol for TMEM267 detection

  • Reduce autofluorescence with sodium borohydride or photobleaching

• Detection system issues:

  • For FITC-conjugated antibodies, ensure proper storage to prevent degradation

  • Check for fluorophore cross-talk in multi-color experiments

How can I improve detection of low-abundance TMEM267?

For proteins with low expression levels:

• Signal amplification methods:

  • Tyramide signal amplification can increase sensitivity 10-100 fold

  • Consider using biotin-streptavidin systems or polymer-based detection

• Sample enrichment:

  • Use subcellular fractionation to concentrate membrane proteins

  • Consider immunoprecipitation before western blotting

• Optimized imaging parameters:

  • Increase exposure time (balancing signal vs. background)

  • Use high-sensitivity cameras and appropriate filter sets

  • Consider confocal microscopy for improved signal-to-noise ratio

• Antibody selection:

  • Choose high-affinity antibodies when available

  • Consider using cocktails of antibodies against different epitopes

What approaches can address cross-reactivity with other TMEM family proteins?

Transmembrane proteins often share structural similarities that can lead to cross-reactivity:

• Epitope selection:

  • Choose antibodies targeting unique regions of TMEM267

  • Avoid antibodies raised against conserved domains

• Validation strategies:

  • Test antibody against recombinant proteins from related TMEM family members

  • Use knockout/knockdown controls for TMEM267

  • Verify results with antibodies targeting different epitopes

• Computational analysis:

  • Perform sequence alignment of potential cross-reactive proteins

  • Identify unique sequences in TMEM267 for developing more specific antibodies

• Absorption controls:

  • Pre-incubate antibody with recombinant related proteins to remove cross-reactive antibodies

  • Compare staining patterns before and after absorption

How can TMEM267 knockout models advance our understanding of this protein's function?

The development of TMEM267 knockout models, similar to the TMEM268 knockout mouse model described in the literature , would significantly advance functional studies:

• Generation approaches:

  • CRISPR-Cas9 gene editing in cell lines and animal models

  • Conditional knockout systems to study tissue-specific functions

  • Inducible systems for temporal control of gene expression

• Phenotypic analysis:

  • Assess effects on cellular morphology, growth, and survival

  • Examine responses to various stimuli (similar to testing LPS response in TMEM268 knockouts)

  • Evaluate potential impacts on immune function, considering TMEM268's role in anti-infectious immunity

• Molecular characterization:

  • Identify dysregulated pathways through transcriptomic and proteomic analyses

  • Examine potential compensatory mechanisms by related proteins

  • Study protein-protein interaction networks in the presence and absence of TMEM267

• Disease models:

  • Evaluate susceptibility to relevant disease models

  • Assess potential as a therapeutic target

What methodological approaches can identify TMEM267 binding partners?

Understanding protein interactions is crucial for elucidating function:

• Co-immunoprecipitation with TMEM267 antibodies:

  • Use validated TMEM267 antibodies for pull-down experiments

  • Analyze precipitated complexes by mass spectrometry

  • Verify interactions with reciprocal co-IP experiments

• Proximity labeling approaches:

  • BioID or APEX2 fusion proteins for in vivo proximity labeling

  • TurboID for rapid labeling of proximal proteins

• FRET/BRET assays:

  • For studying direct protein-protein interactions

  • Useful for dynamic interaction studies in living cells

• Yeast two-hybrid screening:

  • For systematic identification of potential interactors

  • Requires validation in mammalian systems

Based on TMEM268 research, integrin family members would be priority candidates to investigate as potential TMEM267 interactors .

How might TMEM267 expression analysis inform disease research?

Expression pattern analysis can provide valuable insights:

• Tissue and cell-type profiling:

  • Use validated antibodies for immunohistochemical analysis across tissues

  • Single-cell RNA sequencing to identify cell populations expressing TMEM267

  • Compare with TMEM268, which shows high expression in monocytes and macrophages

• Disease association studies:

  • Compare TMEM267 expression in normal vs. disease tissues

  • Correlation analysis with clinical parameters and outcomes

  • Meta-analysis of public gene expression databases

• Regulation studies:

  • Identify transcription factors controlling TMEM267 expression

  • Study potential epigenetic regulation

  • Examine effects of inflammatory mediators on expression (similar to LPS effects on TMEM268)

• Biomarker potential:

  • Evaluate TMEM267 as a diagnostic or prognostic marker

  • Develop sensitive detection methods for clinical samples